Results 91 to 100 of about 433 (169)
Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. [PDF]
JCI InsightSpecht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. +11 moreeuropepmc +1 more sourceIL10R Inhibition Induces Neutrophil Tumoricidal Activity. [PDF]
Cancer Immunol ResKhalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, Lavery JA, Ceglia N, Freeman SS, Maltez VI, Garcia JM, Suek N, Weng CH, Cabanski CR, Monette S, Romin Y, Li Y, Chaligne R, Yellin MJ, Keler T, Maurer DM, Flamar AL, Morgado-Palacin L, Mangarin LM, Harding JJ, Park W, Lyman JP, Maddock S, O'Hara MH, Abou-Alfa GK, Vonderheide RH, O'Reilly EM, Germain RN, Wolchok JD, Merghoub T. +36 moreeuropepmc +1 more sourceAllogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. [PDF]
J Clin OncolSrour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB, Roberts ZJ, Tannir NM, Pal S, Kotecha RR. +15 moreeuropepmc +1 more sourceMolecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer. [PDF]
Clin Cancer ResCowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, Khalil DN, Park W, Rousseau B, Cercek A, Erinjeri J, Yeh R, Do RK, Basturk O, Shia J, Chakravarty D, Berger MF, Schultz N, Gonen M, O'Reilly EM, Jarnagin W, Abou-Alfa GK, Solit DB, Chatila WK, Harding JJ. +26 moreeuropepmc +1 more sourceLong-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. [PDF]
J Clin OncolMedina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA, C-144-01 Investigators. +19 moreeuropepmc +1 more sourceiNOS is a key mediator of anti-PD-1 melanoma therapy response. [PDF]
Front ImmunolNguyen QT, Kim Y, Le THN, Garg S, Balkaran V, Bhathivi T, Chamizo A, Dukes CW, Ward K, Brohl AS, Karapetyan L, Khushalani NI, Eroglu Z, Tarhini AA, Mulé JJ, Markowitz J. +15 moreeuropepmc +1 more source